Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.50 |
| ▸ | KDM4A | O75164 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.50 |
| ▸ | TET3 | O43151 | 2/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056835 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL7172857 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL6056821 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL327411 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL6056894 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL3793029 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL8984493 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL945898 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL8984535 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C | |
| SCHEMBL6056810 | 0.97 | GPR84 (0.64) | GPR84FFAR1TET2KDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837322-B1 | BIODEGRADABLE COATINGS BASED ON AQUEOUS PHA DISPERSIONS | DANIMER IPCO LLC (US) | 2025-03-19 | — | — | EP | claimed |
| US-20250074941-A1 | Polymer Agonists of Mu Opioid Receptors | CYTOGEL PHARMA, LLC | 2025-03-06 | — | — | US | claimed |
| EP-4304951-B1 | HOME COMPOSTABLE AND DEGRADABLE EXTRUSION COATED SUBSTRATES | DANIMER IPCO LLC (US) | 2025-01-15 | — | — | EP | claimed |
| EP-3853304-B1 | BIODEGRADABLE PROFILE EXTRUDED ARTICLES | DANIMER IPCO LLC (US) | 2024-04-17 | — | — | EP | claimed |
| CN-114656442-B | Method for preparing caprolactone from 5-hydroxymethyl furoic acid | 北京大学 | 2023-04-11 | — | — | CN | claimed |
| US-20220251139-A1 | POLYMER AGONISTS OF MU OPIOID RECEPTORS | CYTOGEL PHARMA, LLC | 2022-08-11 | — | — | US | claimed |
| CN-114656442-A | Method for preparing caprolactone from 5-hydroxymethyl furoic acid | 北京大学 | 2022-06-24 | — | — | CN | claimed |
| EP-3959328-A1 | PRODUCTION OF CHEMICALS FROM RENEWABLE SOURCES | Zymochem, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| EP-3710467-A2 | POLYMER AGONISTS OF MU OPIOID RECEPTORS | Cytogel Pharma, LLC (US) | 2020-09-23 | — | — | EP | claimed |
| US-20200270304-A1 | POLYMER AGONISTS OF MU OPIOID RECEPTORS | CYTOGEL PHARMA, LLC | 2020-08-27 | — | — | US | claimed |
| CN-101528917-B | Compositions and methods for preparing stereoisomerically pure statins and synthetic intermediates thereof | CODEXIS, INC. (US) | 2015-07-29 | — | — | CN | claimed |
| CN-104789505-A | Method and strain for preparing cis-3,5-dihydroxyhexanoate compound by reduction and strain | SUZHOU DONGHESHENGCHANG BIOTECHNOLOGY CO LTD | 2015-07-22 | — | — | CN | claimed |
| WO-2015042201-A2 | A HIGH YIELD ROUTE FOR THE PRODUCTION OF COMPOUNDS FROM RENEWABLE SOURCES | ZYMOCHEM INC. (US) | 2015-03-26 | — | — | WO | claimed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | claimed |
| EP-1789470-B1 | COPOLYETHERESTER COMPOSITIONS CONTAINING HYDROXYALKANOIC ACIDS AND SHAPED ARTICLES PRODUCED THEREFROM | DU PONT (US) | 2012-10-31 | — | — | EP | claimed |
| EP-1789470-A1 | COPOLYETHERESTER COMPOSITIONS CONTAINING HYDROXYALKANOIC ACIDS AND SHAPED ARTICLES PRODUCED THEREFROM | E.I.Du pont de nemours and company (US) | 2007-05-30 | — | — | EP | claimed |
| US-7144972-B2 | Copolyetherester compositions containing hydroxyalkanoic acids and shaped articles produced therefrom | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-12-05 | — | — | US | claimed |
| WO-2006010061-A1 | COPOLYETHERESTER COMPOSITIONS CONTAINING HYDROXYALKANOIC ACIDS AND SHAPED ARTICLES PRODUCED THEREFROM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060009611-A1 | Copolyetherester compositions containing hydroxyalkanoic acids and shaped articles produced therefrom | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-01-12 | — | — | US | claimed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | GPR84 60/4885FFAR1 31/4885TET2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.